The expression of toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical toll-like receptor modulators

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 9, 2010, Pages 20-29

  Valins, Whitney ^a   Amini, Sadegh ^a   Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; AGATOLIMOD; AMPLIGEN; ANTINEOPLASTIC AGENT; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CBT SL5; CETUXIMAB; CPG OLIGODEOXYNUCLEOTIDE; DACARBAZINE; EMD 1201081; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIQUIMOD; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; IRS 954; MONTANIDE; MONTANIDE ISA 51; NICOTINAMIDE; NY ESO 1 ANTIGEN; PACLITAXEL; POLYPEPTIDE ANTIBIOTIC AGENT; R 850; RESIQUIMOD; RETINOIC ACID; SOTIRIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG; ZINC;

ACNE; ACNE VULGARIS; ACTINIC KERATOSIS; ARTICLE; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; BOWEN DISEASE; BREAST CANCER; BULLOUS PEMPHIGOID; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOKINE PRODUCTION; DERMATITIS HERPETIFORMIS; DRUG MECHANISM; GENITAL HERPES; HEAD AND NECK CARCINOMA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOTHERAPY; INFLAMMATORY ACNE; KERATINOCYTE; LANGERHANS CELL; LENTIGO; LEPROSY; LUNG NON SMALL CELL CANCER; LUPUS VULGARIS; MELANOMA; METASTASIS; MOLLUSCUM CONTAGIOSUM; NECROBIOSIS LIPOIDICA; NONHODGKIN LYMPHOMA; NONHUMAN; PROPIONIBACTERIUM ACNES; PROTEIN EXPRESSION; PSORIASIS; RADIATION INJURY; RECURRENT CANCER; SKIN CANCER; SKIN DISEASE; SKIN INFLAMMATION; SKIN INJURY; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; THERAPY EFFECT; ULTRAVIOLET B RADIATION; UPREGULATION; VERRUCA PLANTARIS; VERRUCA VULGARIS; VULVA DISEASE; VULVAR INTRAEPITHELIAL NEOPLASIA;

EID: 77957676318     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 1999;285(5428):732-736.
2. Lai Y, Gallo RL. Toll-like receptors in skin infections and inflammatory diseases. Infect Disord Drug Targets. 2008;8(3):144-155.
3. Miller LS. Toll-like receptors in skin. Adv Dermatol. 2008;24:71-87.
4. Sandor F, Buc M. Toll-like receptors. I. Structure, function and their ligands. Folia Biol (Praha). 2005;51(5):148-157.
5. Kang SS, Kauls LS, Gaspari AA. Toll-like receptors: applications to dermatologic disease. J Am Acad Dermatol. 2006;54(6):951-983.
6. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007;13(11):460-469.
7. McInturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol. 2005;125(1):1-8.
8. Tomai MA, Miller RL, Lipson KE. Immune response modifiers: imiquimod and future drugs for modulating the immune response. Drug Discov Today Ther Strateg. 2006;3(3):343-352.
9. Tse K, Horner AA. Update on toll-like receptor-directed therapies for human disease. Ann Rheum Dis. 2007;66(Suppl 3):iii77-iii80.
10. Alvarez JI. Inhibition of toll like receptor immune responses by microbial pathogens. Front Biosci. 2005;10:582-587.
11. McInturff JE, Kim J. The role of toll-like receptors in the pathophysiology of acne. Semin Cutan Med Surg. 2005;24(2):73-78.
12. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002;169(3):1535-1541.
13. Marta Guarna M, Coulson R, Rubinchik E. Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris. FEMS Microbiol Lett. 2006;257(1):1-6.
14. Jugeau S, Tenaud I, Knol AC, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol. 2005;153(6):1105-1113.
15. Krutzik SR, Ochoa MT, Sieling PA, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med. 2003;9(5):525-532.
16. Wu JK, Siller G, Strutton G. Psoriasis induced by topical imiquimod. Australas J Dermatol. 2004;45(1):47-50.
17. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140(12):1490-1495.
18. Noonan FP, DeFabo EC, Kripke ML. Suppression of contact hypersensitivity by UV radiation and its relationship to UV- induced suppression of tumor immunity. Photochem Photobiol. 1981;34:683-689.
19. Rivas JM, Ullrich SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol. 1992;149:3865-3871.
20. Yoshikawa T, Kurimoto I, Streilein JW. Tumor necrosis factor alpha mediates ultraviolet light enhanced expression of contact hypersensitivity. Immunology. 1992;76:254-271.
21. Kock A, Schwarz T, Kirnbauer R, et al. Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin for ultraviolet light. J Exp Med. 1990;172:1609-1614.
22. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet. 1998;22:631-677.
23. Vabulas RM, Ahmad-Nejad P, da Costa C, et al. Endocytosed HSP60 uses toll-like receptor 2 (TLR2) and TLR4 to activate the toll/ interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem. 2001;276:31332-339.
24. Vabulas RM, Braedel S, Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll- like receptor 2/4 pathway. J Biol Chem. 2002;277:20847-20853.
25. Vabulas RM, Ahmed-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002;277:15107-15112.
26. Caramalho I, Lopes-Calcalho T, Oster D, et al. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003;197:403-411.
27. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today. 2007;12(1-2):80-87.
28. Berman B, Amini S, Valins W, Block S. Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother. 2009;10(18):3015-3031.
29. Berman B, Viera M, Amini S, Valins W. Immune response modulators in the treatment of skin cancer. In: Rigel et al, ed. Cancer of the Skin. 2nd ed. Chapter 44. Philadelphia, Pa: Elsevier, Inc. In press.
30. Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205-210.
31. Fife KH, Meng TC, Ferris DG, Liu P. Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. Antimicrob Agents Chemother. 2008;52(2):477-482.
32. Mark KE, Corey L, Meng TC, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis. 2007;195(9): 1324-1331.
33. Shalita AR, Smith JG, Parish LC, et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol. 1995;34(6): 434-437.
34. Grange PA, Raingeaud J, Calvez V, et al. Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. J Dermatol Sci. 2009;56(2):106-112.
35. Kolb H, Burkart V. Nicotinamide in type 1 diabetes. Mechanism of action revisited. Diabetes Care. 1999;22(Suppl 2):B16-B20.
36. Liu PT, Krutzik SR, Kim J, et al. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol. 2005;174(5):2467-2470.
37. Vega B, Jonard A, Michel S. Regulation of human monocyte Toll-like receptor 2 (TLR2) expression by adapalene (abstract). J Eur Acad Dermatol Venereol. 2002: 16:123-124.
38. Tenaud I, Khammari A, Dreno B. In-vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6): 500-506.
39. Dreno B, Trossaert M, Boiteau HL et al. Zinc salts effects on granulocyte zinc concentration and chemotaxis in acne patients. Acta Derm Venereol. 1992;72:250-252.
40. Strauss JS, Stranieri AM. Acne treatment with topical erythromycin and zinc: effect of Propionibacterium acnes and free fatty acid composition. J Amer Acad Dermatol. 1984;11:86-89.
41. Dreno B, Foulc P, Reynaud A, et al. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in-vitro and in-vivo study. Eur J Dermatol. 2005;15(3):152-155.
42. Chvapil M, Stankova L, Zukoski CT et al. Inhibition of some functions of polymorphonuclear leukocytes by in-vitro zinc. J Lab Clin Med. 1977;89:135-146.
43. Dreno B, Amblard P, Agache P et al. Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol. 1989;69:541-543.
44. Dreno B, Moyse D, Alirezai M, et al. Acne Research and Study Group. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology. 2001;203(2): 135-140.
45. Jarrousse V, Castex-Rizzi N, Khammari A, et al. Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol. 2007;17(6):492-496.
46. Ofodile ON. Disifin (sodium tosylchloramide) and Toll-like receptors (TLRs): evolving importance in health and diseases. J Ind Microbiol Biotechnol. 2007;34(12):751-762.
47. Park HS, Jung HY, Park EY, et al. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J Immunol. 173:3589-3593.
48. Beutler B. TLR4: central component of the sole mammalian LPS sensor. Curr Opin Immunol. 2000;12:20-26.
49. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol. 2002;14:103-110.
50. Vulcano M, Dusi S, Lissandrini D, et al. Toll receptor-mediated regulation of NADPH oxidase in human dendritic cells. J Immunol. 173:5749-5756.
51. Van Reenen C, Van Zyl WH, Dicks LM. Expression of the immunity protein of plantaricin 423, produced by Lactobacillus plantarum 423, and analysis of the plasmid encoding the bacteriocin. Appl Environ Microbiol. 2006;72: 7644-7651.
52. Lee YJ, Choi HJ, Kang TW, et al. CBT-SL5, a bacteriocin from Enterococcus faecalis, suppresses the expression of interleukin-8 induced by Propionibacterium acnes in cultured human keratinocytes. J Microbiol Biotechnol. 2008;18(7): 1308-1316.
53. Najar HM, Dutz JP. Topical CpG enhances the response of murine malignant melanoma to dacarbazine. J Invest Dermatol. 2008;128(9):2204-2210.
54. Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs. 2008;17(7): 1051-1065.
55. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117(5):1184-1194.
56. Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine. 2009;27(25-26):3401-3404.
57. Ospelt C, Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol. 2010;42(4):495-505.
58. Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist. ClinicalTrials.gov Identifier: NCT00960752. http://clinicaltrials.gov/ct2/show/NCT00960752. Accessed on May 17, 2010.
59. Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors. ClinicalTrials.gov Identifier: NCT00519363. http://clinicaltrials.gov/ct2/show/NCT00519363. Accessed on May 17, 2010.
60. Phase I randomized, double-blind, placebo-controlled study of topical resiquimod as an adjuvant for NY-ESO1 protein+montanide vaccination in patients with tumors that often express NY-ESO-1. ClinicalTrials.gov Identifier: NCT00821652. http://clinicaltrials.gov/ct2/show/NCT00821652. Accessed on May 17, 2010.
61. Laser and TLR-agonist immunotherapy: a novel autologous melanoma vaccine study. ClinicalTrials.gov Identifier: NCT00453050. http://clinicaltrials.gov/ct2/show/NCT00453050. Accessed on May 17, 2010.
62. ® ISA-51 VG in patients with high risk melanoma in complete clinical remission. ClinicalTrials.gov Identifier: NCT01079741. http://clinicaltrials.gov/ct2/show/NCT01079741. Accessed on May 17, 2010.
63. An explorative, single-center and controlled study to analyze the immune escape mechanisms of HPV-associated lesions and to evaluate the efficiency and mechanisms of imiquimod treatment of vulvar intraepithelial neoplasias 2/3 (VIN) and anogenital warts. ClinicalTrials.gov Identifier: NCT00941811. http://clinicaltrials.gov/ct2/show/NCT00941811. Accessed on May 17, 2010.
64. A Phase II, open-label, 1:1 randomized, controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naive subjects with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). ClinicalTrials.gov Identifier: NCT01040832. http://clinicaltrials.gov/ct2/show/NCT01040832. Accessed on May 17, 2010.
65. A multipeptide vaccine in melanoma patients with evaluation of the injection site microenvironment. ClinicalTrials.gov Identifier: NCT00705640. http://clinicaltrials.gov/ct2/show/NCT00705640. Accessed on May 17, 2010.